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TGN1412The therapeutic monoclonal antibody (mAb) TGN1412 (anti-CD28 superagonist) caused near-fatal cytokine re-
lease syndrome (CRS) in all six volunteers during a phase-I clinical trial. Several cytokine release assays (CRAs)
with reported predictivity for TGN1412-induced CRS have since been developed for the preclinical safety testing
of new therapeutic mAbs. The whole blood (WB) CRA is the most widely used, but its sensitivity for TGN1412-
like cytokine release was recently criticized. In a comparative study, using group size required for 90% power
with 5% signiﬁcance as a measure of sensitivity, we found that WB and 10% (v/v)WB CRAs were the least sensi-
tive for TGN1412 as these required the largest group sizes (n= 52 and 79, respectively). In contrast, the periph-
eral bloodmononuclear cell (PBMC) solid phase (SP) CRAwas the most sensitive for TGN1412 as it required the
smallest group size (n = 4). Similarly, the PBMC SP CRA was more sensitive than the WB CRA for muromonab-
CD3 (anti-CD3) which stimulates TGN1412-like cytokine release (n= 4 and 4519, respectively). Conversely, the
WB CRA was far more sensitive than the PBMC SP CRA for alemtuzumab (anti-CD52) which stimulates FcγRI-
mediated cytokine release (n=8 and 180, respectively). Investigation of potential factors contributing to the dif-
ferent sensitivities revealed that removal of red blood cells (RBCs) from WB permitted PBMC-like TGN1412 re-
sponses in a SP CRA, which in turn could be inhibited by the addition of the RBC membrane protein
glycophorin A (GYPA); this observation likely underlies, at least in part, the poor sensitivity of WB CRA for
TGN1412. The use of PBMC SP CRA for the detection of TGN1412-like cytokine release is recommended in con-
junctionwith adequately powered group sizes for dependable preclinical safety testing of new therapeuticmAbs.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One of the most dangerous side effects caused by the administra-
tion of therapeutic monoclonal antibodies is CRS or “cytokine storm”.
The most dramatic example to date occurred in March 2006, during
the ﬁrst-in-man phase-I clinical trial of the therapeutic mAbblood; PBMCs, peripheral blood
; AQ, Aqueous Phase; RBCs, Red
horin A; CRS, cytokine release
sity culture; IL-2, interleukin-2;
kin-17; TNFα, tumor necrosis
receptor; TCR, T cell receptor.
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sillier),
This is an open access article under thTGN1412. TGN1412 caused severe infusion reactions in all six
healthy volunteers characterized by the rapid systemic release of
high levels of pro-inﬂammatory cytokines later termed a “cytokine
storm” (Suntharalingam et al., 2006). Pre-clinical safety testing, which
included in vitro incubation of TGN1412 in aqueous-phase (AQ) with
human PBMC and intravenous administration of TGN1412 to cynomol-
gus macaques, had both failed to predict an adverse response in man
(TeGenero, 2005; Stebbings et al., 2007). This failure to predict cytokine
release in man demonstrated an urgent need for a new generation of
CRAs that would be both sensitive and predictive of clinical outcome
in man (Vidal et al., 2010). Several groups subsequently developed
CRA methods with reported predictivity for TGN1412, although the
in vivo mechanism resulting in TGN1412-induced cytokine storm in
man is not fully understood. These CRA methods include: PBMC incu-
bated with therapeutic mAbs either wet or dry coated onto tissue cul-
ture plates for SP presentation (Stebbings et al., 2007; Eastwood et al.,
2010, 2013), WB incubated with therapeutic mAbs bound to protein Ae CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2014); high density pre-culture (HDC) of PBMC followed by incubation
with AQ therapeutic mAbs (Rӧmer et al., 2011; Bartholomaeus et al.,
2014); WB or diluted WB incubated with AQ therapeutic mAbs (Wolf
et al., 2012; Bailey et al., 2013); and co-culturing PBMC with AQ thera-
peutic mAbs over human umbilical vein endothelial cells (Stebbings
et al., 2007; Findlay et al., 2011; Dhir et al., 2012), although this latter
approach is not widely used. However, for the safety evaluation of
new therapeutic mAbs there is no consensus regarding which CRA
methods are the most relevant, which controls are the most appropri-
ate, which cytokine measurements are the most appropriate, what
group size should be employed and how that data is best interpreted
(EMA, 2007; Finco et al., 2014).
A recent survey found that the WB CRA was the most widely used
method, even though the WB CRA has been criticized for being poorly
predictive for TGN1412 activity in vivo due to the low levels of cytokine
release obtained and the low frequency of responding donors obtained,
when compared to the PBMC SP CRA and in vivo responses (Finco et al.,
2014; Thorpe et al., 2013). Conversely, it has been argued that the WB
CRA more closely mimics the in vivo environment and contains factors
at physiological concentration that may inﬂuence mechanisms of cyto-
kine release whereas PBMC isolation results in the removal of RBCs,
neutrophils, platelets, serum components and other factors (Wolf
et al., 2012, 2013; Finco et al., 2014). Moreover, WB CRA can be
performed more rapidly and conveniently than PBMC CRA in non-
specialized settings using smaller volumes of blood. Since the conse-
quence of failing to predict an adverse response in man would be very
serious, as occurred in 2006, a sensitive CRA with a high statistical
power of 90% (probability of detecting a response if present) with a sig-
niﬁcance level of 5% (probability of obtaining a false positive or negative
result) is required for the best chance of detecting a true effect if present.
An insensitive CRA is more likely to be underpowered and have a great-
er chance of false positive and negative results due to the requirement
for very large group sizes in excess of numbers typically or that can be
practically employed (Finco et al., 2014). In addition, an insensitive
CRA would lack the dynamic range required to distinguish between
mild,moderate and severe CRS, so it couldn't be claimed to be predictive
of clinical outcome (Thorpe et al., 2013; Stebbings et al., 2013). To better
understand the differences betweenWB and PBMC CRAs, we compared
the most widely used of these methods with a range of therapeutic
mAbs associated with severe (TGN1412; Suntharalingam et al., 2006;
Stebbings et al., 2007), moderate (muronomab-CD3; Suthanthiran
et al., 1989; Chatenoud et al., 1990) and mild-moderate (alemtuzumab
and rituximab; Wing et al., 1996; Moreau et al., 1996; Winkler et al.,
1999; Lim et al., 1999) CRS, using the group size required for 90%
power and 5% signiﬁcance as a measure of sensitivity.
2. Materials and methods
2.1. Therapeutic mAbs, controls and CRA methods
CRAs were performed using the following therapeutic mAbs:
TGN1412 (humanized IgG4k, anti-CD28 superagonist; TeGenero AG),
rituximab (chimeric mouse/human IgG1κ, anti-CD20, mabthera; Hoff-
mann–La Roche Ltd), alemtuzumab (humanized IgG1, anti-CD52,
Campath-1H; Genzyme Corp.), muromonab-CD3 (murine IgG2a, anti-
CD3, Orthoclone-OKT3; Janssen-Cilag Ltd). Puriﬁed human IgG4κ and
IgG1 were used as isotype controls (AMS Biotechnology Ltd, UK) and
anti-CD28 agonist (Biolegend, UK) was used as a control to assess spec-
iﬁcity for a CD28 superagonist. Sodium azidewas removed from control
mAbs using Amicon® Ultra-4 centrifugal ﬁlter units (Millipore Ltd, UK)
and conﬁrmed endotoxin-free using the limulus amebocyte lysate gel
clot test. Since human FcγRI and FcγRIIIa bind murine IgG2a as per
human IgG1, muromonab-CD3 responses were compared to human
IgG1 isotype control (Bruhns, 2012). Phytohaemagglutinin (PHA;
Sigma-Aldrich Ltd, UK) at 10 μg ml−1 was used as a positive control.PBMC SP CRAswere performed bywet coatingwells ofmicrotitre plates
at a mAb concentration of 1 μg well−1 for 1 h, followed by washing to
remove unboundmAb and then the addition of PBMC for 48 h, as previ-
ously described (Eastwood et al., 2010, 2013). PBMC HDC CRAs were
performed by addition of mAb at 1 μg ml−1, to PBMC pre-incubated at
high density for 48 h, and 24 h stimulation, as previously described
(Rӧmer et al., 2011; Bartholomaeus et al., 2014). WB and 10% (v/v)
WB CRAs were performed at a mAb concentration of 5 μg ml−1 and
48 h stimulation, as previously described (Wolf et al., 2012; Bailey
et al., 2013). All concentrationswere chosen for comparabilitywith pre-
viously published ﬁndings on cytokine release using these methods. Al-
though not a publishedmethod,WB SP and 10% (v/v)WB SP CRAswere
performed as per the PBMC SP CRAwith amAb coating concentration of
1 μg well−1, as controls. All assays were carried out in 96-well round
bottom microtitre plates (Sigma Aldrich Ltd), PBMC SP and HDC CRA
utilized 2 × 105 PBMC in 200 μl of complete media per well, the WB
CRA utilized 200 μl of WB per well containing 0.7–2.0 × 106 WBCs and
the 10% (v/v) WB CRA utilized a tenth of the latter in complete media
at 200 μl well−1. CRA comparisons were performed using the same
set of donors, except for the PBMC HDC CRA which utilized a different
set of 8 donors. The effect of selective depletion of RBCs from heparin-
ized WB was assessed, using EasySep™ glycophorin A positive cell de-
pletion cocktail (Stemcell Technologies, UK) according to the
manufacturer's instructions. Brieﬂy, buffy coats were prepared from
whole blood by centrifugation and incubated with anti-glycophorin A
reagent for 15 min at room temperature before addition of magnetic
nanoparticles added and a further incubation for 10 min. RBCs were
then removed by immuno-magnetic separation. Depletion of 95–99%
of RBCs was conﬁrmed by visual assessment. The resultant white
blood cell (WBC) suspension consisting almost entirely of plasma de-
pleted polymorphonuclear leukocytes, lymphocytes and monocytes
was adjusted to 1 × 106 ml−1 in complete media and used in a WBC
SP CRA at 200 μl well−1 and a mAb coating concentration of
1 μg well−1 TGN1412. To investigate inhibition of TGN1412-
associated cytokine release, WBCs were resuspended in autologous
WB or 10–200 μgwell−1 of GYPA (Sigma-Aldrich Ltd)was added. To as-
sess the effect of IL-2 on TGN1412-associated cytokine release,
daclizumab (IL-2R antagonist) at a concentration of 5 μg ml−1 was
added to cells and pre-incubated for 10 min prior to plating in a PBMC
SP CRA as described above. Concentrations of IFNγ, IL-2, IL-13 and IL-8
in culture supernatants weremeasured using custommadeMSD plates,
according to the manufacturer's instructions (Meso Scale Discovery,
USA). TNFα and IL-17 concentrationswere quantiﬁed by ELISA as previ-
ously described (Eastwood et al., 2010, 2013).
2.2. Statistical analysis
Statistical analysis was performed using Minitab 16 software
(Minitab). A general linearmodel was employed for repeatedmeasures
analysis of log10 transformed data using Tukey's test with 95% conﬁ-
dence to counteract for multiple comparisons. Group size requirements
were calculated for paired t-tests on log transformed data to compare
each mAb treatment against the IgG1 control, except for TGN1412
which was compared to the IgG4 and CD28 agonist controls. All mAb
and cytokine response combinationswere assumed to have equally var-
iable responses for each CRA method and the standard deviations used
for the calculations were pooled.
3. Results
3.1. The PBMC SP CRA is highly predictive for TGN1412-induced cytokine
release
The levels of IFNγ, IL-2 and TNFα release following stimulation
with a range of therapeutic mAbs using different CRA methods are
shown in Figs. 1, 2 and 3, respectively. The levels of IL-8, IL-13 and
Fig. 1. Analysis of IFNγ release obtainedwith different CRAmethods: IFNγ release from human (A) PBMC SP (1 μg well−1 coating concentration), (B) PBMC HDC (1 μgml−1), (C)WB and
(D) 10% (v/v) WB CRA (5 μg ml−1) stimulated with the therapeutic mAbs Rituximab, Alemtuzumab, Muromonab-CD3 and TGN1412. PBMC SP and HDC CRA utilized 2 × 105 PBMC in
200 μl of complete media per well, the WB CRA utilized 200 μl of WB per well containing 0.7–2.0 × 106 WBCs of which 2–8 × 105 were lymphocytes and the 10% (v/v) WB CRA utilized
a tenth of the latter in 200 μl well−1. IFNγ release expressed in pgml−1was assessed after 48 h stimulation,with the exception of the PBMCHDCCRAwhich utilizes a 48hHDC followedby
24 h stimulationwithmAbs. PHA at 10 μgml−1 was used as amitogen control. All responses were compared against IgG1 isotype control with the exception of TGN1412,whichwas com-
pared against IgG4κ isotype control. Signiﬁcant results are denoted by asterisks (repeated measures analysis of log10 transformed data using Tukey's method with 95.0% conﬁdence —
*p b 0.05, **p b 0.001, ***p b 0.0001). The geometric mean of group responses is denoted by a horizontal bar. Donor responses shown are n= 10 from 3 independent experiments, except
for the PBMC HDC CRA for which n= 8 from 2 independent experiments. CRA comparisons were performed using the same set of donors, except for the PBMC HDC CRA which utilized a
different set of 8 donors.
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signiﬁcant IFNγ (p b 0.0001 and 9908 pg ml−1), IL-8 (p b 0.0001 and
136,048 pg ml−1), IL-13 (p b 0.0001 and 2451 pg ml−1) and IL-17
(p b 0.0001 and 346 pg ml−1) release with TGN1412 (Fig. 1, Table 1).
Both the PBMC SP and PBMC HDC CRAs produced signiﬁcant IL-2 re-
lease (both p b 0.0001, 5469 pg ml−1 and 158 pg ml−1, respectively)
with TGN1412 (Fig. 2). In order of magnitude, the PBMC SP, PBMC
HDC, 10% (v/v) WB andWB CRAs all produced signiﬁcant TNFα release
(p b 0.0001 and 19,090 pg ml−1, p b 0.0001 and 748 pg ml−1, p =
0.0046 and 488 pg ml−1, p = 0.0003 and 125 pg ml−1, respectively),
with TGN1412 (Fig. 3). Low but signiﬁcant amounts of IFNγ (p =
0.0015 and 2.4 pg ml−1), IL-2 (p = 0.0019 and 15 pg ml−1) and IL-13
(p b 0.0001 and 41 pg ml−1) release was observed with the 10% (v/v)
WB CRA and CD28 agonist control (Figs. 1 and 2, Table 1). Signiﬁcant
IL-13 (p = 0.0044 and 300 pg ml−1) release was also noted with the
PBMC SP CRA and CD28 agonist control, but the level obtained with
TGN1412was in comparison signiﬁcantly (p b 0.0001) greater (Table 1).
In order of magnitude, the PBMC SP, PBMC HDC and 10% (v/v) WB
CRAs all produced signiﬁcant IFNγ (p b 0.0001 and 4035 pg ml−1,
p = 0.0006 and 92 pg ml−1, p b 0.0001 and 9.7 pg ml−1, respectively)
and IL-2 (p b 0.0001 and 547 pg ml−1, p = 0.0185 and 54 pg ml−1,
p b 0.0001 and 25 pg ml−1, respectively) release following stimulation
with muromonab-CD3 (Figs. 1 and 2). Only the PBMC SP and PBMC
HDC CRAs produced signiﬁcant TNFα release (p b 0.0001 and
25,437 pg ml−1, p b 0.0001 and 1173 pg ml−1, respectively) with
muromonab-CD3 (Fig. 3), whereas, only the PBMC SP and 10% (v/v)
WB CRAs produced signiﬁcant IL-8 (p b 0.0001 and 193,381 pg ml−1,
p b 0.0001 and 2855 pg ml−1, respectively) and IL-13 (p b 0.0001 and1625 pg ml−1, p = 0.0001 and 26 pg ml−1, respectively) release with
muromonab-CD3 (Table 1). Only the PBMC SP CRA produced signiﬁcant
IL-17 (p b 0.0001 and 629 pg ml−1) release with muromonab-CD3
(Table 1). No signiﬁcant cytokine release was measured using the WB
CRA with muromonab-CD3.
3.2. The WB CRA is predictive for alemtuzumab-induced cytokine release
Only the WB CRA produced signiﬁcant IFNγ (p b 0.0001 and p =
33 pg ml−1) and IL-8 (p = 0.0089 and 7162 pg ml−1) release with
alemtuzumab (Fig. 1, Table 1). Both the PBMC HDC and WB CRAs in-
duced signiﬁcant TNFα release (p = 0.0005 and 81 pg ml−1, p =
0.0105 and 83 pg ml−1, respectively) with alemtuzumab (Fig. 3). No
signiﬁcant cytokine release with alemtuzumab was observed using
the PBMC SP and 10% (v/v)WB CRAs (Figs. 1, 2 and 3, Table 1). Interest-
ingly, if presentation of alemtuzumab in a WB CRA was changed from
AQ to SP then no signiﬁcant cytokine releasewas detected (Supplemen-
tary Table 1). However, using the WB or 10% (v/v) WB SP CRA, low but
signiﬁcant IL-2 (p = 0.0097 and 24 pg ml−1, p = 0.0025 and
7.6 pg ml−1, respectively) and TNFα (p = 0.0043 and 135 pg ml−1,
p= 0.0414 and 11 pgml−1) release was achievedwith TGN1412 (Sup-
plementary Table 1). No signiﬁcant cytokine release was observed with
rituximab using any CRA method tested.
3.3. The WB CRA is not predictive for TGN1412-induced cytokine release
Shown in Table 2 are estimated group sizes required by each CRA
method to detect signiﬁcant cytokine release at the 5% signiﬁcance
Fig. 2. Analysis of IL-2 release obtained with different CRA methods: IL-2 release from human (A) PBMC SP (1 μg well−1 coating concentration), (B) PBMC HDC (1 μg ml−1), (C) WB and
(D) 10% (v/v)WBCRA (5 μgml−1) stimulatedwith the therapeuticmAbs rituximab, alemtuzumab,muromonab-CD3 and TGN1412. PBMC SP andHDCCRAutilized 2× 105 PBMC in 200 μl
of complete media per well, theWB CRA utilized 200 μl ofWB per well containing 0.7–2.0 × 106WBCs of which 2–8 × 105were lymphocytes and the 10% (v/v)WB CRA utilized a tenth of
the latter in 200 μl well−1. IFNγ release expressed in pg ml−1 was assessed after 48 h stimulation, with the exception of the PBMC HDC CRA which utilizes a 48 h HDC followed by 24 h
stimulationwithmAbs. PHA at 10 μgml−1 was used as amitogen control. All responseswere compared against IgG1 isotype control with the exception of TGN1412, whichwas compared
against IgG4κ isotype control. Signiﬁcant results are denoted by asterisks (repeatedmeasures analysis of log10 transformed data using Tukey'smethodwith 95.0% conﬁdence— *p b 0.05,
**p b 0.001, ***p b 0.0001). The geometric mean of group responses is denoted by a horizontal bar. Donor responses shown are n = 10 from 3 independent experiments, except for the
PBMCHDC CRA forwhich n=8 from2 independent experiments. CRA comparisonswere performedusing the same set of donors, except for the PBMCHDCCRAwhich utilized a different
set of 8 donors.
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muromonab-CD3 and TGN1412 compared to isotype control. For the
detection of TGN1412 responses the least sensitive method was the
10% (v/v) WB CRA followed by the WB CRA which required group
sizes of n= 79 and 52, respectively. TheWB CRAwas essentially insen-
sitive to muromonab-CD3 as it required a group size of n= 4519. Para-
doxically, the 10% (v/v)WB and 10% (v/v)WB SP CRAs were the second
most sensitive methods for muromonab-CD3 as they only required
group sizes of n = 9 and n = 8, respectively (Table 2). The PBMC SP
CRA was the most sensitive method for TGN1412 and muromonab-
CD3, requiring a group size of just n = 4 for both mAbs, whereas the
PBMC HDC CRA required group sizes of n = 27 and 31 for TGN1412
and muromonab-CD3, respectively. Compared to the PBMC HDC CRA,
the WB SP CRA required a smaller group size (n = 13) for TGN1412,
but a larger group size (n = 43) for muromonab-CD3 (Table 2). While
theWB CRAwas the most sensitive method for alemtuzumab requiring
a group size of n = 8, the 10% (v/v) WB SP, 10% (v/v) WB, PBMC SP,
PBMC HDC and SP WB CRA were not sensitive to alemtuzumab as
these required group sizes of n = 66, 114, 180, 341 and 5069, respec-
tively (Table 2). Group sizes required for 80% power are shown in Sup-
plementary Table 2.
Although individual donors responded to the CD28 agonist control
with IFNγ, IL-2 and TNFα release in the WB CRA, group responses
were not signiﬁcant (Figs. 1, 2 and 3, respectively). In the 10% (v/v)
WB CRA signiﬁcant but very low IFNγ (2.4 pg ml−1, p = 0.0015) and
IL-2 release and (27 pgml−1, p b 0.0001), but not TNFα release, was ob-
tained with the CD28 agonist control (Figs. 1 and 2, respectively). Todetermine the speciﬁcity of different CRA for a CD28 superagonist,
group sizes were estimated compared to CD28 agonist controls
(Table 2). For the WB, 10% (v/v) WB and 10% (v/v) SP WB CRAs the
group sizes required to distinguish between TGN1412 and the CD28 ag-
onist control were more than doubled, but for the PBMC SP, PBMC HDC
andWB SP CRAs the group size requirements barely changed (Table 2).
By calculating the group sizes required for 90% signiﬁcance with the
omission of TNFα release, the robustness of these results were further
tested by excluded reliance upon a single cytokine (Supplementary
Table 3). For the PBMC SP CRA the group size required to detect a
TGN1412 response was unaffected (n = 4) whereas for the WB and
10% (v/v)WB CRA the group sizes requiredwere dramatically increased
(n = 1135 and n = 18,843, respectively).
3.4. RBCs, GYPA and daclizumab inhibit TGN1412-induced cytokine release
Depletion of RBCs fromWB allowed signiﬁcant (all p b 0.0001) IL-
2 (10,220 pgml−1), IFNγ (8366 pgml−1), IL-13 (3113 pgml−1), IL-8
(41,913 pg ml−1), TNFα (11,750 pg ml−1) and IL-17 (156 pg m1−1)
release to occur with TGN1412 in a WBC SP CRA (Fig. 4). Re-
suspension of WBC in WB prior to stimulation with TGN1412 in a
SP CRA signiﬁcantly (all p b 0.0001) inhibited IL-2, IFNγ, IL-13,
TNFα and IL-17, but not IL-8 release (Fig. 4). The addition of GYPA
to WBC SP CRA also signiﬁcantly inhibited TGN1412 mediated IL-2
(p b 0.0001), IFNγ (p b 0.0001), IL-13 (p = 0.0017), TNFα (p =
0.0026) and IL-17 (p b 0.0001) release, but not IL-8 release (Fig. 4).
A second batch of GYPA used in the range 10–200 μg well−1 gave
Fig. 3.Analysis of TNFα release obtainedwith different CRAmethods: TNFα release fromhuman (A) PBMC SP (1 μgwell−1 coating concentration), (B) PBMCHDC (1 μgml−1), (C)WBand
(D) 10% (v/v) WB CRA (5 μg ml−1) stimulated with the therapeutic mAbs rituximab, alemtuzumab, muromonab-CD3 and TGN1412. PBMC SP and HDC CRAs utilized 2 × 105 PBMC in
200 μl of complete media per well, the WB CRA utilized 200 μl of WB per well containing 0.7–2.0 × 106 WBCs of which 2–8 × 105 were lymphocytes and the 10% (v/v) WB CRA utilized
a tenth of the latter in 200 μl well−1. IFNγ release expressed in pgml−1was assessed after 48 h stimulation,with the exception of the PBMCHDCCRAwhich utilizes a 48hHDC followedby
24 h stimulationwithmAbs. PHA at 10 μgml−1 was used as amitogen control. All responses were compared against IgG1 isotype control with the exception of TGN1412,whichwas com-
pared against IgG4κ isotype control. Signiﬁcant results are denoted by asterisks (repeated measures analysis of log10 transformed data using Tukey's method with 95.0% conﬁdence —
*p b 0.05, **p b 0.001, ***p b 0.0001). The geometric mean of group responses is denoted by a horizontal bar. Donor responses shown are n= 10 from 3 independent experiments, except
for the PBMC HDC CRA for which n= 8 from 2 independent experiments. CRA comparisons were performed using the same set of donors, except for the PBMC HDC CRA which utilized a
different set of 8 donors.
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signiﬁcant (p b 0.0001) increase in IL-8 release with the addition of
GYPA to WB SP CRA control wells was retrospectively ascribed to
contamination with 6.0 IU mg−1 of endotoxin and the second batch of
GYPA with 2.4 IU mg−1 endotoxin (data not shown). Contamination
of GYPA with these levels of endotoxin was not associated with any
reduction in cell viability when used in the range 10–200 μg well−1
(Supplementary Fig. 2). Addition of daclizumab to PBMC SP CRA sig-
niﬁcantly reduced IFN-γ (p = 0.011), IL-13 (p = 0.0001), TNF-α
(p = 0.031) and IL-17 (p = 0.031) release with TGN1412, but did
not signiﬁcantly reduce IL-8 release (Fig. 5). No signiﬁcant reduction
in IL-2 release was noted with TGN1412 and daclizumab (Fig. 5).
4. Discussion
This comparative study demonstrates that in terms of the group size
required to detect a real effect, the PBMC SP CRA is by far the most sen-
sitive method for the detection of TGN1412-like cytokine release (n =
4), whereas WB CRAs are the least sensitive (n = 52–79). Of concern
is a survey which reports that the majority of laboratories and contract
research organizations useWBCRAswith between n=6 and 14 donors
to detect a TGN1412-like response, which our results show is statistical-
ly underpowered and therefore poorly predictive of clinical outcome in
man (Finco et al., 2014). Despite recent criticism, it is argued that the
WB CRA is a valid approach to detect TGN1412-like cytokine release
(Thorpe et al., 2013;Wolf et al., 2013). Yet, even for candidate screening
of therapeutic mAbs, where only relatively large effects may be of inter-
est and a power of 80% may be sufﬁcient since false positive or negativeresultswould not have serious consequences,WBCRAs still require very
large group sizes (n = 39–59).
Signaling through the co-stimulatorymolecule CD28, either by its
natural ligands CD80/CD86 or an agonist mAb cannot induce T cell
activation and cytokine release without simultaneous engagement
of the T cell receptor, which restricts responses to antigen-speciﬁc
cells which typically comprise only 0.01–1.0% of the total T cell pop-
ulation (Acuto and Michel, 2003; Rudd and Schneider, 2003; Harari
et al., 2004; Calarota and Baldanti, 2013). In contrast, a CD28
superagonist such as TGN1412 is able to dispense with primary sig-
naling through the TCR and is capable of polyclonal activation of all
antigen-speciﬁc T cells (Lühder et al., 2003; Stebbings et al., 2007;
Waibler et al., 2008). Therefore, greater levels of cytokine release
would be expected in a CRA stimulated with a CD28 superagonist
compared to a CD28 agonist, used here as a control. Yet here the re-
sponses of WB CRAs to a CD28 agonist control resembled or in cer-
tain cases exceeded that of TGN1412, indicating poor speciﬁcity
and very weak responses to TGN1412. Some cytokine release at
very low levels would be expected within a subset of donors as a
CD28 agonist would be capable of the re-stimulation of recently
primed T-cells (e.g. recent vaccination or infection). It is possible
that AQ TGN1412 is behaving like a CD28 agonist in the WB CRAs
and that the low levels of cytokine release observed within a subset
of donors may have been misinterpreted as a superagonist response
in the absence of appropriate controls. For example, the use of
natalizumab (anti-α4 integrin) as an isotype control for TGN1412
is not recommended as it suppresses background TNFα and IL-8 re-
lease, which may lead to over interpretation of weak positive or
Ta
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TGN1412 responses were compared with a CD28 agonist control
the group size requirement for 90% power more than doubled for
WB CRAs (n = 117–284), further illustrating poor speciﬁcity and
low responses to TGN1412. Moreover, greater cytokine release over-
all was obtained with a CD28 agonist control than TGN1412 using
the 10% (v/v) WB CRA method. In contrast, the group sizes required
for the PBMC SP to detect a TGN1412 response compared with a
CD28 agonist control hardly changed (n = 5).
The PBMC HDC CRA was the third most sensitive method for the
detection of TGN1412 induced cytokine release, in terms of the
group size required (n = 27). However, the 31 pg ml−1 of IFNγ re-
lease obtained here is considerably lower than the N1000 pg ml−1
reported by Rӧmer et al. (2011). One difference between these as-
says is that we only used freshly isolated PBMC, whereas Rӧmer
et al. (2011) used PBMC recovered from leukoreduction ﬁlters
which are discarded after the preparation of therapeutic red blood
cell concentrates from individual blood donations. We have found
that cells recovered from leukoreduction ﬁlters gave higher back-
ground cytokine release implying non-speciﬁc priming occurs dur-
ing processing, which may have enhanced IFNγ release with
TGN1412. A longer stimulation of 48 h with the PBMC HDC CRA
may have resulted in higher levels of IFNγ release, as is seen with
the PBMC SP CRA. Alternatively, the majority of IFNγ release report-
ed by Rӧmer et al. (2011) may not in fact have come from CD4+ T
cells. As the level of TGN1412-associated IL-2 release with the
PBMC HDC was comparable with Rӧmer et al. (2011), both methods
likely stimulate similar levels of CD4+ T cells since this cytokine is
restricted to production by this cell type, whereas IFNγ release is
not restricted so it could have come from a different cell type e.g.
monocytes or neutrophils. Intriguingly, the WB SP CRA included as
a control, but which is akin to the protein A bead WB CRA method
(Walker et al., 2011; Xiong et al., 2014), proved more sensitive for
TGN1412 than the PBMC HDC CRA (n = 13), likely due to signiﬁcant
IL-13 release in addition to TNFα and IL-2, a situation not observed
with muromonab-CD3. Differences in the pattern of TGN1412-
associated cytokines detected with different CRA may reﬂect the
strength of the signal; with TNFα being the easiest to detect, follow-
ed by IL-2 and IFNγ, then IL-13 and IL-17 being the hardest to detect.
Conversely, different patterns of cytokine release may reﬂect the in-
volvement of different subsets or mechanisms or in the case of WB
CRA the inability to detect certain cytokines due to with the inhibito-
ry effects of GYPA.
Criticism of SP presentation of therapeutic mAbs as artiﬁcial or the
use of PBMC compared to WB as unrepresentative of the in vivo envi-
ronment is not valid as only the combination of both these elements
produces the most sensitive CRA to detect TGN1412-like cytokine re-
sponses with a power of 90% and a signiﬁcance level of 5% (Stebbings
et al., 2007; Rӧmer et al., 2011; Wolf et al., 2012). It is reported that
binding of TGN1412 to inhibitory FcγRIIb is necessary for in vitro
superagonistic activitywith the PBMCHDCCRA and in vivowith agonis-
tic anti-TNFR antibodies (Bartholomaeus et al., 2014; Hussain et al.,
2015; Li and Ravetch, 2012; White et al., 2014). If FcγRIIIb cross-
linking was responsible for the TGN1412 cytokine storm in vivo, then
SP presentation of mAbs in vitro at least partially emulates it. A qualita-
tive factor to consider is that TGN1412 caused the release of high levels
of multiple pro-inﬂammatory cytokines in trial volunteers and that the
PBMC SP CRA similarly produced high levels of all 6 cytokinesmeasured
here, with the caveat that one is an in vivo response and the other an
in vitro assay. In contrast, the WB CRA produced signiﬁcant release of
just one out of six cytokines: TNFα at levels 153 fold lower than the
PBMC SP CRA. The next best CRA with TGN1412 was the PBMC HDC
CRA which produced signiﬁcant release of TNFα and IL-2, but at levels
that were still 25.5 and 34.6 times lower, respectively, than with the
PBMC SP CRA. Thus, in terms of the range andmagnitude of cytokine re-
lease obtained here we have concluded that compared to other CRA the
Table 2
Estimated group sizes required to detect cytokine release with different CRA methods with a power of 90%: Group size requirements for human PBMC SP, PBMC HDC, WB and 10% (v/v)
WB CRA, WB SP and 10% (v/v) WB SP were calculated for paired t-tests on log transformed data to compare each therapeutic mAb against IgG1 isotype control, with the exception of
TGN1412which was compared to IgG4κ isotype control and a CD28 agonist*. All therapeutic mAb and cytokine response combinations were assumed to have equally variable responses
for each CRAmethod and the standard deviations used for the calculations were pooled standard deviations (all 6 cytokine responses for the different therapeutic mAbs). The group sizes
given for each therapeutic mAb would detect the difference observed in cytokine release for each CRA method with a power of 90% at the 5% signiﬁcance level.
CRA method Power analysis Alemtuzumab Muromonab-CD3 TGN1412 TGN1412*
PBMC SP Relative mean 1.2 32.9 110.9 71.8
Group size required 180 4 4 5
PBMC HDC relative mean 1.5 4.0 4.4 6.7
Group size required 341 31 27 19
WB Relative mean 5.5 0.9 2.2 1.7
Group size required 8 4519 52 117
10% (v/v) WB Relative mean 1.5 13.7 2.1 0.7
Group size required 114 9 79 284
WB SP Relative mean 0.9 3.4 3.4 4.3
Group size required 5069 43 13 13
10% (v/v) WB SP Relative mean 1.8 24.3 2.4 1.4
Group size required 66 8 46 313
49S. Vessillier et al. / Journal of Immunological Methods 424 (2015) 43–52PBMC SPmethodmore closely reﬂects the observed biological response
to TGN1412 in vivo (Suntharalingam et al., 2006; Stebbings et al., 2007;
Eastwood et al., 2013).
Selective depletion of the RBC component in WB demonstrated its
central role in inhibiting TGN1412-associated cytokine release in the
WB CRA. However, it should be noted that this result was achieved in
the context of SP presentation and that depletion of RBCs alone would
be unlikely to fully restore responses to TGN1412 as it would be similar
to the insensitive PBMC CRA which failed to predict the severity of the
in vivo outcome (TeGenero, 2005; Stebbings et al., 2007). Conversely,
the absence of a RBC component in PBMC explains why the PBMC SP
CRA proved to be a much more sensitive method for the detection of
TGN1412-like cytokine release thanWB CRAs. Since TGN1412 predom-
inantly stimulates T cells, then this ﬁnding is also consistent with the re-
ported underestimation of antigen-speciﬁc T cell cytokine responses
usingWB assays (Stebbings et al., 2007; Hoffmeister et al., 2003). An ex-
amination of the literature provided a potential mechanism to account
for the ability of RBCs to block the response to TGN1412: GYPA, a
majormembrane glycoprotein of RBCs, can interactwith IL-2 and inhib-
it IL-2-dependent T cell proliferation (Chu and Sharom, 1992). This po-
tential mechanism was conﬁrmed when puriﬁed GYPA was shown to
block TGN1412-associated cytokine release in a dose dependent man-
nerwhen added to aWBC SP CRA. Therefore, the presence of RBCs likely
at least partially explains the poor sensitivity of WB CRAs for TGN1412-
associated cytokine release, mediated through the abundant RBCmem-
brane protein GYPA (106 copies per cell).
TGN1412 and CD28 stimulation in vitro are both characterized by IL-
2 release (Stebbings et al., 2007; van Berkel and Oosterwegel, 2006).
Moreover, TGN1412-associated IL-2 release has been ascribed to the
stimulation of CD4+ effector memory T cells and shown to be dysregu-
lated (Eastwood et al., 2010, 2013). Although daclizumab-mediated in-
hibition of IL-2 signaling signiﬁcantly inhibited TGN1412-associated
TNFα, IFNγ, IL-13 and IL-17 release, it did not inhibit IL-2 release, imply-
ing that this cytokine ampliﬁes the release of other cytokines. Since
CD4+ effector memory T cells are more responsive to IL-7 and IL-15
than IL-2, then they would be less sensitive to daclizumab, whereas
CD4+ naïve and central memory T cells are more responsive to IL-2
so would be sensitive to daclizumab (Geginat et al., 2001). However,
the inhibition of cytokine release by daclizumab was not as profound
as that observed with RBCs or GYPA. Some IL-2 signaling may have oc-
curred via the intermediate-afﬁnity IL-2R (βγc chain complex) present
on resting T cells and CD56bright NK cells, since daclizumab only blocks
the high-afﬁnity IL-2R (αβγc chain complex) present on activated T
cells (Sheridan et al., 2011; Liao et al., 2013). Alternatively, GYPA may
also be interacting with other cytokines to suppress TGN1412-
associated cytokine release or the measurement of those cytokines.
Alemtuzumab does not stimulate T cell mediated cytokine release but
rather activating FcγR (FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa) mediatedcytokine release from NK cells, monocytes and neutrophils (Wing
et al., 1996; Hu et al., 2009; Siders et al., 2010). Neutrophils account
for 40–75% of total WBC but are depleted during density gradient isola-
tion of PBMC, which may explain the poor sensitivity of PBMC SP CRA
for alemtuzumab-associated cytokine release. Conversely, the presence
of neutrophils in WB may be responsible for the greater sensitivity of
WB CRA for alemtuzumab, compared to the PBMC SP CRA. Neutrophils
can also inhibit T cell responses which may explain the opposing sensi-
tivities of WB and 10% (v/v) WB CRA for muromonab-CD3 and
alemtuzumab if related to the dilution of this component (McKenna
et al., 2009; Afonso et al., 2010).
While high levels of alemtuzumab-associated cytokine release were
observed with the PBMC SP CRA, only levels of TNFα release markedly
exceeded the levels of other cytokines compared to the isotype control
due to the high background. This background was likely caused by
activating FcγR-mediated cytokine release due to cross-linking
caused by SP presentation, as it is observed with therapeutic mAbs
of the IgG1 subclass that have activating FcγR mediated effector
function e.g. alemtuzumab (Eastwood et al., 2013). No background
was observed with TGN1412 since agonistic and antagonistic
therapeutic mAbs tend to be of the IgG4 subclass due to its very
low FcγRIIa, FcγRIIc and FcγRIIIa binding afﬁnity or have been
engineered to silence unwanted activating FcγR binding (Ascierto
et al., 2010; Alegre et al., 1992). Conversely, the small amount of cy-
tokines produced in WB CRA assays raises the biological signiﬁcance
of results even when they are statistically signiﬁcant when com-
pared to isotype controls e.g. 33 pg ml−1 of IFNγ with alemtuzumab
in the WB CRA. However, even lower levels than this are considered
signiﬁcant by some proponents of WB CRA, which questions the sig-
niﬁcance and validity of very low levels of cytokine release. The va-
lidity of statistically signiﬁcant but low level cytokine release may
be enhanced if the patterns of cytokines released are consistent
with a particular mechanism or cellular repertoire. For example, in
the case of IFNγ release with alemtuzumab in the WB CRA it was
accompanied by signiﬁcant TNFα and IL-8 release but no T cell-
associated IL-2 release, which is consistent with an activating
FcγRs, mediated mechanism. However, for TGN1412 only signiﬁcant
TNFα release was observed with theWB CRA, which alone cannot be
ascribed to a particular mechanism and when excluded from the analy-
sis dramatically increases the group size requirement (n=1135) to the
point of insensitivity. In contrast, exclusion of TNFα release has no effect
on the predictive power of the PBMC SP CRA (n = 4) because the re-
sponse ismuch broader and not reliant upon a single cytokine response.
The presence of RBCs does not appear to inhibit alemtuzumab asso-
ciated cytokine release, presumably because this does not involve a T
cell mediated mechanism driven by IL-2 and GYPA is not known to af-
fect other pro-inﬂammatory pathways e.g. IL-1 (Chu and Sharom,
1992). NK cells have been implicated in alemtuzumab mediated
Fig. 4. RBCs andGYPA inhibit TGN1412-associated cytokine release: (A) IL-2, (B) IFNγ, (C) IL-13, (D) IL-8, (E) TNFα and (F) IL-17 release expressed in pgml−1was assessed using a human
WBC SP CRA stimulated for 48 h with a coating concentration of 1 μg well−1 of TGN1412 and IgG4κ isotype control. PHA at 10 μg ml−1 was used as a mitogen control. WBCs consisted of
RBCs and plasma depleted polymorphonuclear leukocytes, lymphocytes and monocytes resuspended in complete media and adjusted to 1 × 106 ml. WBCs +WB consisted of WBCs re-
suspended in autologousWB.WBCs+GYPA consisted ofWBCs in completemedia towhich 200 μgwell−1 of GYPAwas added. Signiﬁcant results are denoted by asterisks (repeatedmea-
sures analysis of log10 transformed data using Tukey's method with 95.0% conﬁdence — *p b 0.05, **p b 0.001, ***p b 0.0001). The geometric mean of group responses is denoted by a
horizontal bar. Donor responses shown are n = 8 from 2 independent experiments.
50 S. Vessillier et al. / Journal of Immunological Methods 424 (2015) 43–52cytokine release but as these are not depleted by PBMC isolation they
are unlikely to account for observed differences between PBMC SP and
WB CRA sensitivity (Wing et al., 1996). Rituximab is associatedwith ad-
verse events in patients with B-cell chronic lymphocytic leukemia (B-
CLL), ascribed to activating FcγRsmediated cytokine release, but we ob-
served no signiﬁcant rituximabmediated cytokine releasewith any CRA
(Winkler et al., 1999; Lim et al., 1999).We have previously detected NK
cell cytokine production with rituximab in a PBMC SP CRA when using
intracellular cytokine staining as the readout, but here there was insuf-
ﬁcient released cytokine for quantiﬁcation (Stebbings et al., 2013). Since
we used normal healthy donors for PBMC then it is possible that when
compared to B-CLL patients there were insufﬁcient B-cell targets for ri-
tuximab to stimulate signiﬁcant cytokine release. Enriching the B-cell
fraction of normal donorWB to emulate B-CLL patientsmay have result-
ed in more signiﬁcant cytokine release. Rituximab is not negative in allCRA (Walker et al., 2011), in particular IL-6 release and B-cell activation
is prominent in vitro and in vivo but this cytokine was not included in
our panel (Agarwal et al., 2004; Jones et al., 2014).
The levels of cytokine release detected across the board with the
PBMC SP CRA and TGN1412 are vastly higher than those generated
using the WB CRA. In terms of group size required for 90% power and
5% signiﬁcance, the PBMC SP CRA is highly predictive for TGN1412
andWBCRA are poorly predictive. Inhibition of TGN1412-associated cy-
tokine release by RBCs/GYPA provides a clear and convincing explana-
tion for the observed differences in cytokine levels release between
the PBMC and WB CRA, at least when using a SP format. It is clear that
a “one size ﬁts all” approach for the preclinical safety testing of thera-
peutic mAbs does not work because different mechanisms of cytokine
release require different CRA for dependable sensitivity in conjunction
with appropriately powered groups.
Fig. 5.Daclizumab inhibits TGN1412-associated cytokine release: (A) IL-2, (B) IFNγ, (C) IL-13, (D) IL-8, (E) TNFα and (F) IL-17 release expressed in pgml−1 was assessed using a human
PBMC SPCRA stimulated for 48 hwith a coating concentration of 1 μgwell−1 of TGN1412 and IgG4κ isotype control. PHA at 10 μgml−1was used as amitogen control. The inﬂuence of pre-
incubation of PBMC for 10 min with 1 μg ml−1 of daclizumab (anti-CD25) on cytokine release with TGN1412 was compared. Signiﬁcant results are denoted by asterisks (repeated mea-
sures analysis of log10 transformed data using Tukey's method with 95.0% conﬁdence — *p b 0.05, **p b 0.001, ***p b 0.0001). The geometric mean of group responses is denoted by a
horizontal bar. Donor responses shown are n = 10 from 3 independent experiments.
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